Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | RO7425781 |
| Trade Name | |
| Synonyms | RO 7425781|RO-7425781|RG6234|RG-6234|RG 6234|Formitamig |
| Drug Descriptions |
RO7425781 (RG6234) is a bispecific antibody that targets GPRC5D expressed on tumor cells and CD3 expressed on T-lymphocytes, potentially resulting in enhanced antitumor immune response and inhibition of tumor growth (Blood (2022) 140 (Supplement 1): 10137-10139, Blood (2022) 140 (Supplement 1): 2091-2092). |
| DrugClasses | CD3 Antibody 119 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Carfilzomib + RO7425781 | Carfilzomib RO7425781 | 0 | 1 |
| Daratumumab + RO7425781 | Daratumumab RO7425781 | 0 | 1 |
| RO7425781 | RO7425781 | 0 | 2 |